Product Description
IGN002 is a novel recombinant protein comprised of anti-CD20 antibody (rituximab) fused to human IFN_2b by a peptide linker.
Mechanisms of Action: CD20 Antagonist
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Assertio Holdings
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IGN002-201 | P1 |
Withdrawn |
Lymphoma, Non-Hodgkin |
2025-07-01 |
84% |
2022-03-12 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
| NHL | P1 |
Terminated |
Lymphoma, Non-Hodgkin |
2018-05-04 |
71% |
2022-03-12 |
Primary Completion Date|Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/05/2022 |
News Article |
Spectrum Pharmaceuticals Announces Strategic Restructuring |
|
03/30/2021 |
News Article |
Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update |
|
02/23/2021 |
News Article |
Spectrum Pharmaceuticals Announces Two Presentations at Upcoming ESMO TAT Virtual Congress 2021 |